Evidence map›Paper›PMID 30623893›Full record

ArticleMedical science monitor : international medical journal of experimental and clinical research2019

Prognostic Value of Upregulation of Myristoylated Alanine-Rich C-Kinase Substrate in Gastric Cancer.

Ruiliang Quan, Zhongliang Ning, Yongcang Wang, Wei Yu, Haixing Zhu

Open access · hybridAbstract read
In one paragraph

Article in Medical science monitor : international medical journal of experimental and clinical research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.3field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Identification of Hub Genes and Pathways in Gastric Adenocarcinoma Based on Bioinformatics Analysis.Medical science monitor : international medical journal of experimental and clinical research · 2020
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Ruiliang QuanDepartment of Gastrointestinal Surgery, Anhui Provincial Cancer Hospital, Hefei, Anhui, China (mainland).
Zhongliang NingDepartment of Gastrointestinal Surgery, Anhui Provincial Cancer Hospital, Hefei, Anhui, China (mainland).
Yongcang WangDepartment of Gastrointestinal Surgery, Anhui Provincial Cancer Hospital, Hefei, Anhui, China (mainland).
Wei YuDepartment of Gastrointestinal Surgery, Anhui Provincial Cancer Hospital, Hefei, Anhui, China (mainland).
Haixing ZhuDepartment of Gastrointestinal Surgery, Anhui Provincial Cancer Hospital, Hefei, Anhui, China (mainland).
Anhui Provincial Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND Accumulating evidence suggests a connection of Myristoylated alanine-rich C-kinase substrate (MARCKS) with several physiological and pathological processes. However, the relevance of MARCKS in gastric cancer (GC) needs to be elucidated. MATERIAL AND METHODS The abundance of MARCKS in GC tissues was assessed using techniques of immunohistochemistry (IHC) and quantitative real-time PCR (qRT-PCR). Moreover, the MARCKS expression profile in the TCGA database was analyzed through an online website analysis. We also investigated MARCKS function using cell wounding and Matrigel invasion assays. RESULTS TCGA analysis and our data suggest that transcript abundance and protein level of MARCKS was higher in GC tumor samples compared with peri-tumor tissues. There was a remarkable association of upregulated MARCKS with the cell differentiation (P<0.001), T stage (P=0.034), and N stage (P=0.002) followed by advanced TNM phase (P=0.008). Furthermore, it was predicted that higher expression of MARCKS is linked to poor overall survival (P=0.015) and disease-free survival (P=0.020), and that high levels of MARCKS function as an independent prognostic marker, as shown by multivariate Cox regression analysis in prediction of poor overall (HR=0.408; 95% confidence interval=0.247-0.674; P<0.001) and disease-free survival rates (HR=0.525; 95% confidence interval=0.216-0.584; P<0.001). GC cells showed significant reduction in cell migration and invasion upon depletion of MARCKS as noted through Matrigel invasion and cell wounding assays. Further analyses showed that silencing MARCKS impeded the epithelial-mesenchymal transition (EMT). CONCLUSIONS Our study indicates that elevated expression of MARCKS is significantly associated with metastatic capability of GC cells, and MARCKS overexpression can serve as a biomarker of GC poor prognosis.

Indexed as

AdultAgedAged, 80 and overAnimalsCell Line, TumorChinaDisease-Free SurvivalEpithelial-Mesenchymal TransitionFemaleHumansImmunohistochemistryIntracellular Signaling Peptides and ProteinsKaplan-Meier EstimateMaleMembrane ProteinsMiceIntracellular Signaling Peptides and ProteinsMARCKS protein, humanMembrane ProteinsMyristoylated Alanine-Rich C Kinase Substrate

Identifiers

PMID30623893
PMCPMC6338009
OpenAlexW2910660765

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.